March 2025
This month we look at life sciences M&A – will 2025 see a pick-up? Plus: Pearson’s Sally Johnson on the education company’s approach to M&A; Tom Rowe-Jones of LAVA Advisory Partners on the challenges of advising in an accountancy firm takeover; and private equity investment in Scotland.
Long read: Life sciences and biotech M&A
News and views
March 2025
An update on PISCES, the Navigating Power and Politics event, the Faculty AGM and Bayes annual 'look ahead'.
Read moreJon Moulton on due diligence
Jon Moulton explains that due diligence is forever evolving, but external factors mean providers must be careful about scope.
Read moreHenry Whorwood on early-stage finance
Early stage investment is slowing, but there may be local headwinds says Beauhurst's Henry Whorwood.
Read moreGlobal investment and M&A
Insight: Post-offer intention statements
Innovation and sustainable recovery
Insider dealing: Applied Nutrition’s London listing
Roadshow: Scotland
Future advisory professionals
Lessons in dealmaking
Sally Johnson, CFO of education services company Pearson, talks about the importance of a clear strategy and how M&A plays its part.
Read moreListen and learn
Linda Nguyenova, investor and deal origination lead at BGF, says listening to entrepreneurs is key to learning what makes a business tick.
Read moreAll on board
Tom Rowe-Jones from LAVA Advisory Partners says exploring all options for equity partners is vital for M&A in the accountancy sector.
Read more